| 6 | #8 |
|--------------|-------------------------------|
| | Approved for use through 10/3 |
| Detect and T | melament Office, LLC OFFICE |

| | | | | | | - | |
|------------|--------------|---------------|---------------|---------------------------------|--|------------------|--|
| | Under the Pa | | | | tion of information unless it contains a valid OMB | control number | |
| / C | TPE | Substitute fo | or form 1449. | WPTO | Con | nplete if Known | |
| | CI OB ? | 4.7 | | TION DISCLOSURE NT BY APPLICANT | Application Number | 09/699,003 | |
| (F) | ME TRAD | EMARITE | (use as ma | ny sheets as necessary) | Fillian Date | | |
| | | | | | Filing Date | October 26, 2000 | |
| | i | | | | First Named Inventor | M. Rigdon Lentz | |
| | | | | | Group Art Unit | 3762 | |
| | | | | | Examiner Name | P. Bianco | |
| | Sheet | 1 | of | 3 | Attorney Docket Number | LEN 101 CIP CON | |

| | U.S. PATENT DOCUMENTS | | | | | | | | | | |
|-----------------------|-----------------------|---|---------------------|---|-----------------------------------|--|--|--|--|--|--|
| Examiner Initials* | Cite No.1 | | US Patent Document | Name of Patentee or Applicant of Cited Document | Date of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | | | |
| | | Number Kind Code ² (if known) | | | | | | | | | |
| UZ | | 5,980,887 | isner, et al. | 11-09-1999 | | | | | | | |
| 2K | | 6,017,527 | Maraskovsky, et al. | 01-25-2000 | RECEIVED | | | | | | |
| | | | | | OCT 1 4 2003 | | | | | | |
| | | | | | | | | | | | |
| | | | | | TECHNOLOGY CENTER H3700 | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| | | | | F | OREIGN PATENT DOCUMEN | TS | | | | | | | | |
|-----------------------|--------------|----------|-------------|--------------------------------------|-----------------------|--|--|--|--|------|--|---|---|---|
| Examiner Initials* | Cite No.1 | | | | | | | Foreign Patent Document | | ment | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM- DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
| | | Office.3 | Number⁴ | Kind Code ⁵ (if known) | 1 | | rigules Appeal | | | | | | | |
| SUZ | | PCT | WO 91/09967 | | Celltech Ltd. | 07-11-1991 | | ┢ | | | | | | |
| Out? | | PCT | WO 01/37873 | | Lentz | 05-31-2001 | | | | | | | | |
| | | | | + | | | | | | | | | | |
| | | \vdash | | | | - | ······································ | <u> </u> | | | | | | |
| | - | | | + | | | | ⊢ | | | | | | |
| | | | 2 | | | -L | | | | | | | | |

| | $ \cdot$ \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot | | | |
|----------------------|--|-----------------|--------|--|
| Examine Signature | Solbrance | Date Considered | 2-2-04 | |
| | | | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

| Substitute for form 1449A/PTO INFORMATION DISCLOSURE | | | | | Complete If Known | | | | |
|---|------|--------------|---------|--------------------------------|------------------------|------------------|--|--|--|
| at OB | [Gos | INFOF | RMATION | DISCLOSURE | Application Number | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | EMENT E | BY APPLICANT ets as necessary) | | OCT 1 4 2003 | | | |
| | | | | | Filing Date | October 26, 2000 | | | |
| 1 | | | | | First Named Inventor | M. Rigdon Lentz | | | |
| | | | | | Group Art Unit | 3762 | | | |
| | | | | | Examiner Name | P. Bianco | | | |
| Sheet | 1 | 2 | of | 3 | Attorney Docket Number | LEN 101 CIP CON | | | |

| | | OTHER ART NON PATENT LITERATURE DOCUMENTS | | | | |
|-------------------------|--|---|---|--|--|--|
| Examiner's Initials* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the als* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the atticle (when appropriate), title of the article (when appropriate), ti | | | | | |
| RMS | | ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," Cancer Res. 51: 5602-5607 (1991). | | | | |
| | | AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," <i>Science</i> 233: 747-751 (1986). | _ | | | |
| | | CLACKSON, et al., "Making of antibody fragments using phage display libraries," Nature 352: 624-688 (1991). | | | | |
| | | DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991) | | | | |
| | | DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," <i>J. Clin. Invest</i> 89: 1690-1693 (1992). | | | | |
| | | ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993). | | | | |
| | | EY, et al., "Isolation of pure IgG ₁ , IgG _{2a} , and IgG _{2b} immunoglobins from mouse serum using protein A- Sepharose," <i>Immunochemistry</i> 15:429-436 (1978). | | | | |
| | | KABAT, et al., eds., <u>Sequences of Proteins of Immunological Interest</u> , 4 th ed., U.S Dept. Health & Human Services: Bethesda, MD (1987). | - | | | |
| | | KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Purif.</i> 11: 150-157 (1993). | - | | | |
| and | | LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997). | | | | |

| E | | | | | |
|-------------------------|-------------|-----------------|----|------|--|
| Examiner's Signature | Description | Date Considered | 7- | 2-04 | |
| | | | | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

| Please type | a plus sign | (+) inside | this box - |
|-------------|-------------|------------|------------|
| | | | |

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | ute for form | | | o a collection of information unless it contains a v | | | | |
|--|--|-------------------------|--|--|--|----------------------|----------------------------|--|--|
| on of the order of | | | | | C | complete if Known RE | CEIVE | | |
| ENTE TEAB | | ATEME | NT E | I DISCLOSURE BY APPLICANT eets as necessary) | Application Number | 09/699,003 0 C T | T 1 4 2003 DGY CENTER R | | |
| | | (use as ma | ily Sile | oous as nocessary) | Filing Date | October 26, 2000 | | | |
| | | | | | First Named Inventor | M. Rigdon Lentz | | | |
| | | | | | Group Art Unit | 3762 | | | |
| | | | | | Examiner Name | P. Blanco | P. Bianco | | |
| heet | 3 | 3 0 | f | 3 | Attorney Docket Number | LEN 101 CIP CON | | | |
| | | | | OTHER ART N | NON PATENT LITERATURE DOCUM | MENTS | | | |
| Examiner's Initials* | Cite No.1 | | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | | | |
| PMB | | PANKA, et digoxin an | PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti- digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988). | | | | | | |
| 1 | RUDIKOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979- | | | | | | | | |

| | | OTHER ART - NON PATENT LITERATURE DOCUMENTS | |
|-------------------------|--------------|--|---|
| Examiner's Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | Ť |
| Plub | | PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti- digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988). | |
| 1 | | RUDIKOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982). | |
| 1 | | SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo," Cell. Immunol. 200: 81-87 (2000). | |
| Pur | | SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999). | |
| | - | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | 1 | |

| Examiner's | $O(\mathcal{O}_{\mathbf{a}})$ | Date Considered | 0 0 0 1 | |
|------------|-------------------------------|-----------------|---------|--|
| Signature | Sel transit | | 2-2-04 | |
| | | | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.